A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany

References

• Blumenauer V, Czeromin U, Fehr D, et al. D.I.R-annual 2016 - the German IVF-registry. J Reproduktionsmed Endokrinol. 2017;14(6):272–305.
   Google Scholar
• Berg Bringham K, Cadier B, Chevreul K. The diversity of regulation and public financing of IVF in Europe and its impact on utilization. Hum Reprod. 2013;28(3):666–675. doi:10.1093/humrep/des41823223400
   PubMed Web of Science ®Google Scholar
• Rauprich O, Bockenheimer-Lucis G, Thorn P, Wendehorst C. Sollen Kinderwunschbehandlungen von den Krankenkassen finanziert werden? Ethische und rechtliche Aspekte [Shall ART treatments be publicly financed? Ethical and legal aspects]. In: Bockenheimer-Lucius G, Thorn P, Wendehorst C, editors. Umwege zum eigenen Kind: Ethische und rechtliche Herausforderungen an die Reproduktionsmedizin 30 Jahre nach Louise Brown [Detours to a Child of One’s Own: Ethical and Legal Challenges of Reproductive Medicine 30 Years after Louise Brown] Göttingen: Universitätsverlag Göttingen; 2008:31–47.
   Google Scholar
• Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2015;14(7):CD009577.26171903
   PubMed Web of Science ®Google Scholar
• Van Wely M, Kwan I, Burt AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;16(2):CD005354.21328276
   PubMed Web of Science ®Google Scholar
• Bals-Pratsch M, Bühler K, Krüssel J, Wendelken M, Dahncke W, Kupka MS. Extended analyses of the German IVF registry (D·I·R): andrological aspects, medical economical assumptions related to the shift from IVF to ICSI and stimulation with gonadotropins. J Reproduktionsmed Endokrinol. 2010;7(1):40–44.
   Google Scholar
• Fragoulakis V, Pescott CP, Smeenk JM, et al. Economic evaluation of three frequently used gonadotrophins in assisted reproduction techniques in the management of infertility in the Netherlands. Appl Health Econ Health Policy. 2016;14(6):719–727. doi:10.1007/s40258-016-0259-927581117
   PubMed Web of Science ®Google Scholar
• Katzorke T, Verhoeven H, Blechschmidt J, Kohler M, Kelly E. Follitropin-alfa ovarian stimulation during assisted reproduction treatment: a national collaborative study. Reprod Biomed Online. 2001;3(2):98–103.12513870
   PubMedGoogle Scholar
• Lass A, McVeigh E. Routine use of r-FSH follitropin alfa filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK. Reprod Biomed Online. 2004;9(6):604–610.15670403
   PubMed Web of Science ®Google Scholar
• Lehert P, Schertz JC, Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol. 2010;8:112. doi:10.1186/1477-7827-8-11220846363
   PubMed Web of Science ®Google Scholar
• Nawroth F, Tandler-Schneider A, Bilger W. Multicenter, noninterventional, post-marketing surveillance study to evaluate dosing of recombinant human follicle-stimulating hormone using the redesigned follitropin alfa pen in women undergoing ovulation induction. Drug Healthc Patient Saf. 2015;7:63–68. doi:10.2147/DHPS.S7669325926755
   PubMedGoogle Scholar
• Trew GH, Brown AP, Gillard S, et al. In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review. Reprod Biol Endocrinol. 2010;8:137. doi:10.1186/1477-7827-8-13721059191
   PubMed Web of Science ®Google Scholar
• Weiss N. Gonadotrophin products: empowering patients to choose the product that meets their needs. Reprod Biomed Online. 2007;15(1):31–37.17623531
   PubMed Web of Science ®Google Scholar
• Rettenbacher M, Andersen AN, Garcia-Velasco JA, et al. A multi-centre phase 3 study comparing efficacy and safety of Bemfola® versus Gonal-f® in women undergoing ovarian stimulation for IVF. Reprod Biomed Online. 2015;30(5):504–513. doi:10.1016/j.rbmo.2015.01.00525735918
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Kuczynski W, Mueller A, Bias P. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reprod Biol Endocrinol. 2016;14:1. doi:10.1186/s12958-015-0135-826733057
   PubMed Web of Science ®Google Scholar
• Trappe H. Assisted reproductive technologies in Germany: a review of the current situation In: Kreyenfeld M, Konietzka D, editors. Childlessness in Europe: Contexts, Causes, and Consequences. Cham: Springer International Publishing; 2017:269–288.
   Google Scholar
• European Medicines Agency. Biosimilars in the EU; information guide for healthcare professionals; 2017 Available from: https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 130, 2019.
   Google Scholar
• Bassett RM, Driebergen R. Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reprod Biomed Online. 2005;10(2):169–177.15823219
   PubMed Web of Science ®Google Scholar
• Hugues JN, Durnerin IC. Gonadotrophins-filled-by-mass versus filled-by-bioassay. Reprod Biomed Online. 2005;10(Suppl 3):11–17.
   Google Scholar
• Mastrangeli R, Satwekar A, Cutillo F, Ciampolillo C, Palinsky W, Longobardi S. In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f). PLoS One. 2017;12(9):e1084139. doi:10.1371/journal.pone.0184139
   Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH). European Medicines Agency (EMA); 2013 Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-non-clinical-clinical-development-similar-biological-medicinal-products-containing_en.pdf. Accessed 130, 2019.
   Google Scholar
• Gizzo S, Ferrando M, Lispi M, Ripellino C, Cataldo N, Buhler K. A cost-effectiveness modelling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live-birth outcome in Germany, Italy and Spain. J Med Econ. 2018;21(11)1096-1101.
   Web of Science ®Google Scholar
• Gizzo S, Garcia-Velasco JA, Heiman F, Ripellino C, Buhler K. A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility. Int J Womens Health. 2016;8:683–689. doi:10.2147/IJWH.S11868727994486
   PubMed Web of Science ®Google Scholar
• Grynberg M, Murphy C, Dore C, et al. A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. J Med Econ. 2019;22:108–115. doi:10.1080/13696998.2018.1551226
   Web of Science ®Google Scholar
• La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014;20(1):124–140. doi:10.1093/humupd/dmt03724077980
   PubMed Web of Science ®Google Scholar
• Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616–1624. doi:10.1093/humrep/der09221505041
   PubMed Web of Science ®Google Scholar
• Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400,135 treatment cycles. Hum Reprod. 2011;26(7):1768–1774. doi:10.1093/humrep/der10621558332
   PubMed Web of Science ®Google Scholar
• Bundesverband Reproduktionsmedizinischer Zentren Deutschlands e.V. (BRZ). Costs for biopsy needle, sperm processing medium. Available from: http://www.repromed.de/. Accessed 130, 2018.
   Google Scholar
• Lauer-Fischer GmbH WEBAPO® InfoSystem. ATC-group G03GA [ updated August 1, 2017]. Available from: https://www.cgm.com/lauer-fischer/index.de.jsp. Accessed 81, 2017.
   Google Scholar
• Geschäftsverkehr(GKV)-Verband der Privaten Krankenversicherung e.V. and Deutsche Krankenhausgesellschaft; 2017 Available from: http://www.dkgev.de/media/file/27711.Vereinbarung_Bundesbasisfallwert_2017. Accessed 130, 2018.
   Google Scholar
• Rauprich O, Berns E, Vollman J. Who should pay for assisted reproductive techniques? Answers from patients, professionals and the general public in Germany. Hum Reprod. 2010;25(5):1225–1233. doi:10.1093/humrep/deq05620228390
   PubMed Web of Science ®Google Scholar
• Legro RS, Wu X, Barnhart KT, Farquhar C, Fauser BC, Mol B. Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statementdaggerdouble dagger. Hum Reprod. 2014;29(10):2075–2082. doi:10.1093/humrep/deu21825217611
   PubMed Web of Science ®Google Scholar
• Pasch RRC, D’Hoghe T, Longobardi S. Live Birth Rate (LBR), Ongoing Pregnancy Rate (OPR) And Ovarian Hyperstimulation Syndrome (OHSS) risk with originator versus biosimilar recombinant follitropin alfa: a pooled analysis of clinical trial data. PMU40. ISPOR Europe; 1110–14; 2018; Barcelona, Spain.
   Google Scholar
• Silverio N, Batista AR, Sequeira L. Biosimilars, are they really cost saving? The case of recombinant human follicle stimulating hormone in Portugal. Value Health. 2015;18(7):A736. doi:10.1016/j.jval.2015.09.2820
   Web of Science ®Google Scholar
• Silverio N, Botica F, Batista A. Cost-effectiveness of recombinant human follicle stimulating hormone biosimilars in Portugal. Value Health. 2016;19(7):A402–A403. doi:10.1016/j.jval.2016.09.323
   Web of Science ®Google Scholar
• GKV-Spitzenverband. GKV-Verband der Privaten Krankenversicherung e.V. and Deutsche Krankenhausgesellschaft; 2017 Available from: http://www.dkgev.de/media/file/27711.Vereinbarung_Bundesbasisfallwert_2017. Accessed 130, 2018.
   Google Scholar